Haleon (HLN) Q2 2026 earnings review
North America Rebounds, Funding Investment Amid Restructuring
Haleon delivered solid 2.6% organic revenue growth in H1 2026, successfully navigating a severe 4.7% contraction in Respiratory Health driven by a weak cold and flu season. The standout story is the reversing trend in North America, which returned to volume-led growth (Q2 organic +3.1%, volume/mix +2.0%) after a turbulent 2025 plagued by retailer destocking. Productivity initiatives drove a massive 140bps expansion in adjusted gross margin, funding a 3.2% increase in A&P spend and an 8.2% jump in adjusted operating profit. However, the operational success didn't reach the statutory bottom line—reported operating profit fell 2.6% due to £169m in restructuring charges related to the new operating model.
🐂 Bull Case
After a year of painful retailer destocking and share losses, Q2 organic revenue in NA grew 3.1%, driven by a healthy +2.0% in volume/mix. Shelf resets and distribution gains are actively taking hold.
Adjusted gross margin expanded 140bps to 66.5%. With SKUs down 27% since 2024 and continuous manufacturing trials succeeding, the company is successfully generating the cash needed to fund A&P and R&D.
🐻 Bear Case
Reported operating profit fell 2.6% to £1,172m, weighed down heavily by £169m in restructuring costs for the new operating model. Management must prove these changes will genuinely yield the projected £175-200m in savings.
Europe organic growth was sluggish at 0.6%, with Q2 volume/mix contracting 1.8%. Value-seeking behavior in Germany and CEE is driving down overall market volumes.
⚖️ Verdict: 🟢
Bullish. The return to volume-led growth in North America proves the 2025 destocking issues were temporary. Haleon's ability to expand margins by 140bps while simultaneously increasing marketing spend demonstrates excellent operational leverage.
Key Themes
North America Drives the Recovery
Reversing. North America flipped from being a massive drag in 2025 to a growth engine. Q2 organic revenue grew 3.1%, with a 2.0% positive contribution from volume/mix. This was a result of improved execution across retailer partnerships, completed shelf resets, and stronger media effectiveness in a challenging macro environment. This proves that the destocking headwinds are largely in the rearview mirror.
Oral Health Outperformance
Accelerating. Oral Health continues to be Haleon's most reliable growth engine, jumping 7.3% organically in H1. Growth was supported by the Sensodyne Clinical platform, with Sensodyne Clinical Repair launching in the US and early data showing it is the #1 innovation in the category by value. Furthermore, geographic expansion of parodontax in China drove strong double-digit growth.
Productivity Savings Fueling Margins
Stable. The supply chain strategy is paying significant dividends. Adjusted gross profit grew 4.7% at CER, driving a 140bps margin expansion to 66.5%. The company has reduced SKUs by 27% and formulations by 26% since the beginning of 2024. This operating leverage allowed Haleon to increase A&P investment by 3.2% while still delivering 120bps of adjusted operating profit margin expansion.
Respiratory Health Drag
Decelerating. Respiratory Health was the sole laggard in the portfolio, with organic revenue plunging 4.7% in H1. This was heavily impacted by a weak cold and flu season across North America, Central & Eastern Europe, and China. In APAC specifically, Q2 saw significant double-digit declines at CER from lower incidence levels. Allergy was also flat, trending below prior year levels as the season progressed.
Restructuring Costs Suppressing Statutory Profits
Reversing. While adjusted metrics look excellent, actual reported operating profit fell 2.6% to £1,172m. This divergence was entirely driven by £169m in restructuring costs (up from £26m a year ago) related to the 'Win as One' operating model transformation. While management projects £175-200m in annualized gross savings over the next two years, the immediate friction is a heavy burden on current profitability.
Macro Weakness in Europe
Decelerating. The new Europe reporting segment posted anemic 0.6% organic growth in H1, with Q2 volume/mix contracting 1.8%. Management cited a weak consumer backdrop with value-seeking behavior in markets like Germany and Central and Eastern Europe. While Haleon claims to be outperforming the market, the overall category volumes are shrinking.
Other KPIs
Stable. Up slightly from £734m in H1 25. Strong adjusted operating profit growth and lower cash interest were partially offset by higher tax payments. Enabled the completion of £457m of the £500m 2026 share buyback allocation, highlighting consistent capital return capability.
Stable. Total borrowings stand at £8.25bn, with Net Debt at £7.51bn. Management considers 2.5x to be the optimal leverage ratio for the business, striking a balance between M&A optionality, shareholder returns, and maintaining a strong investment-grade balance sheet.
Guidance
Stable. Unchanged from prior guidance. With H1 coming in at 2.6%, this implies an expected acceleration in the second half of the year, driven by North American shelf resets, further innovation rollouts, and a reduced drag from Respiratory Health comps.
Stable. Unchanged and strictly at constant currency. H1 delivered 8.2% growth, tracking perfectly against this target. Notably, management now expects a slightly positive foreign exchange translation impact on both net revenue and adjusted operating profit for the full year.
Key Questions
North America Volume Sustainability
North America Q2 volume/mix grew 2.0%. Given the extensive destocking in 2025, how much of this Q2 growth represents underlying consumption increases versus one-time pipeline restocking associated with shelf resets?
Restructuring Tapering
With £169m of restructuring charges in H1 alone, mostly related to severance and the new operating model, what is the expected cadence for the remaining transition costs in H2 2026 and FY27?
Combating European Downtrading
You noted value-seeking behavior causing volume declines across the overall market in Germany and CEE. Is Haleon planning to introduce more value-tier offerings in Europe similar to the strategy in India and Brazil, or will you strictly defend premium positioning?